- Suspensions of AstraZeneca vaccine rollout over side-effect fears will fuel global vaccine hesitancy despite swift resumption of use
- Reduced confidence in AstraZeneca will risk diminishing demand in EU, raising risk of insufficient protection to prevent further waves next winter
- AstraZeneca’s role in COVAX means suspensions will undermine demand globally, potentially prolonging pandemic in poorer countries
Denmark, Norway and Iceland announced on 11 March they would suspend use of the Oxford/AstraZeneca ChAdOx-1 coronavirus (COVID-19) vaccine, citing concerns over side-effects, specifically blood clotting disorders.
Falanx Assynt is a global intelligence consultancy and leading provider of geopolitical, strategic and business risk analysis since 2003. Falanx Assynt is part of Falanx Group Ltd (LON:FLX) which, through its subsidiaries, provides cyber defence and intelligence services to blue chip and government clients worldwide.